Assetmark Inc. Has $115,000 Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Assetmark Inc. raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1,370.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,205 shares of the company’s stock after acquiring an additional 4,851 shares during the period. Assetmark Inc.’s holdings in Teva Pharmaceutical Industries were worth $115,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Diversify Advisory Services LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after purchasing an additional 496 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after purchasing an additional 664 shares in the last quarter. Metis Global Partners LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after purchasing an additional 860 shares in the last quarter. DGS Capital Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the third quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock valued at $246,000 after purchasing an additional 872 shares in the last quarter. Finally, Williamson Legacy Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 1.7% in the fourth quarter. Williamson Legacy Group LLC now owns 57,824 shares of the company’s stock valued at $1,274,000 after purchasing an additional 979 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on TEVA. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. StockNews.com lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Friday, March 7th. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Barclays reduced their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Finally, Bank of America reduced their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $16.38 on Friday. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The stock has a market cap of $18.57 billion, a price-to-earnings ratio of -11.29, a PEG ratio of 1.44 and a beta of 0.82. The business has a 50 day moving average of $18.28 and a 200-day moving average of $18.30. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.